MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101
Phase 1 study finds high rates of remission and tolerability with sonrotoclax + obinutuzumab in treatment-naive CLL, highlighting effectiveness against MRD.
Key Points
Encouraging antitumor activity was seen with sonrotoclax plus obinutuzumab in treatment-naive CLL patients.
The overall response rate was 93% in the 320 mg cohort, suggesting significant efficacy.
This observational analysis focused on MRD status, showing high rates of uMRD4 after treatment cycles.
No clinical or laboratory tumor lysis syndrome events occurred, indicating a favorable safety profile.